Date: Friday, November 6, 2020
Session Type: Poster Session A
Session Time: 9:00AM-11:00AM
Background/Purpose: Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome–coronavirus-2 (SARS-CoV-2) infection, is a global pandemic causing havoc. There is a knowledge gap regarding the use of use of immunomodulation and anti-inflammatories in patients with COVID-19 and the optimal treatment is yet to be defined. The repurposing of colchicine for the treatment of COVID-19 has been suggested based in its immunomodulatory, anti-inflammatory, and anti-viral properties.
Methods: A single-center propensity score matched cohort study, including all consecutive COVID-19 patients, with confirmed SARS-CoV-2 infection admitted to community teaching hospital between March 1, 2020 and May 12, 2020 was performed. Patients were stratified according to the receipt of colchicine. The primary endpoint was defined as all-cause in-hospital death within 28-day follow-up.
Results: In total, 50 patients were included in the 1:1 matched cohort study. The mean age of the total study population was 58.3 years (range: 26 – 90 years), and 24% (n=12) were female. The most prevalent chronic comorbidities included hypertension (54%; n=27), diabetes (40%; n=20), obesity (46%, n=23), and chronic pulmonary disease (16%; n=8). At the end of the 28 day follow-up, patients receiving colchicine were approximately 2 times more likely to be discharged from the hospital (odds ratio, 2.11; 95% confidence interval, 0.63 – 7.1; p=0.225) and when comparing mortality, there were 3 deaths (12%) in patients receiving colchicine versus 10 deaths (40%) in the groups receiving standard of care (odds ratio, 0.21; 95% confidence interval, 0.05 – 0.87; p=0.032).
Conclusion: To our knowledge, this is the first cohort report using colchicine for the treatment of COVID-19. Treatment with colchicine led to a higher rate of discharge from the hospital and was associated with a decrease in mortality in patients with severe COVID-19. These observations warrant further investigation in large colchicine controlled clinical trials.
To cite this abstract in AMA style:Brunetti L, Diawara O, Tsai A, Firestein B, Nahass R, Poiani G, Schlesinger N. Colchicine to Weather the Storm in Hospitalized Patients with COVID-19 [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/colchicine-to-weather-the-storm-in-hospitalized-patients-with-covid-19/. Accessed November 23, 2020.
« Back to ACR Convergence 2020
ACR Meeting Abstracts - https://acrabstracts.org/abstract/colchicine-to-weather-the-storm-in-hospitalized-patients-with-covid-19/